Compared with chemotherapy, treatment with first-generation and second-generation EGFR-TKIs has resulted in a median progression-free survival (PFS) of 9 to 13 months in patients with advanced NSCLC, and the median PFS provided by third-generation drugs was 18.9 months (9–12). Here, EGFR is linked to non-small cell lung carcinoma.